Amneal Pharmaceuticals, Inc Class A Common Stock

Yahoo Finance • last month

Amneal to Report Third Quarter 2024 Results on November 8, 2024

BRIDGEWATER, N.J., October 08, 2024--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its third quarter 2024 financial results on Friday, November 8, 2024, prior to market open. The... Full story

Yahoo Finance • 2 months ago

Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases

Amneal to construct state-of-the-art manufacturing facilities and utilize existing manufacturing network to ensure supply of Metsera’s portfolio of novel injectable and oral development programs, including GLP-1 and amylin receptor agonist... Full story

Yahoo Finance • 3 months ago

Amneal Reports Second Quarter 2024 Financial Results

‒ Q2 2024 Net Revenue of $702 million; GAAP Net Income of $6 million; Diluted Income per Share of $0.02 ‒ ‒ Adjusted EBITDA of $162 million; Adjusted Diluted EPS of $0.16 ‒ ‒ Raising 2024 Full Year Guidance ‒ ‒ CREXONT® U.S. FDA approva... Full story